SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Pierrocks, Gaintrader
Search This Board:
Last Post: 5/29/2015 10:14:20 PM - Followers: 167 - Board type: Free - Posts Today: 10


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

**Important: Mike Tomás' personal StemCellCEO blog!**

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Statement of Changes in Beneficial Ownership (4) 05/26/2015 04:31:50 PM
BHRT News: Quarterly Report (10-q) 05/05/2015 05:05:00 PM
BHRT News: Amended Statement of Ownership (sc 13g/a) 04/08/2015 10:04:05 AM
BHRT News: Annual Report (10-k) 03/16/2015 09:06:59 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:02:11 PM
#14846  Sticky Note Sunrise, FL – April 15, 2015 – Bioheart, Gaintrader 04/17/15 11:44:05 AM
#15259   You are correct except it's at 5% micromoney 05/29/15 10:14:20 PM
#15258   I was under the impression that all the InvestorStemCell 05/29/15 09:49:31 PM
#15257   I was under the impression that all the InvestorStemCell 05/29/15 09:15:32 PM
#15256   Daily chart shaping up 514 05/29/15 07:07:58 PM
#15255   Quote, "(not including the $3m in deferred salary/bonus)" ?? Captain Kirk 05/29/15 01:05:24 PM
#15252   Good summary. Do you know what the InvestorStemCell 05/29/15 12:38:36 PM
#15251   Looks like BMAK doing the ole "raise the Captain Kirk 05/29/15 10:07:29 AM
#15250   still here too, at 0,0072 pepemartinez 05/29/15 08:49:55 AM
#15249   I won't be shaken either. Holding strong andyshow 05/28/15 04:48:46 PM
#15248   A treatment for the untreatable. Resurrection of InvestorStemCell 05/28/15 04:44:27 PM
#15247   Your DD is appreciated Can you give me InvestorStemCell 05/28/15 02:58:28 PM
#15246   The best piece of financial journalism ever done Captain Kirk 05/28/15 01:02:46 PM
#15245   It might be in Frank Dodd as far Solarman 05/28/15 12:46:55 PM
#15244   They can't shake me. I know the potential... Investaholic33 05/28/15 12:39:03 PM
#15243   No retail buyers for this security. A Black InvestorStemCell 05/28/15 12:35:01 PM
#15242   If you can make a change like you InvestorStemCell 05/28/15 12:15:48 PM
#15241   $125 purchase of shares pushed BHRT into the green. Solarman 05/28/15 11:26:05 AM
#15240   Maybe, some people know that I might be Solarman 05/28/15 11:21:00 AM
#15239   Bid dropping again- it's all the .004's now: Captain Kirk 05/28/15 10:42:02 AM
#15238   $3 million market cap hmmmm. If I Solarman 05/28/15 12:01:02 AM
#15237   Wonder who :) wealththrupennies 05/27/15 08:50:43 PM
#15236   Thanks for sharing Go $BHRT $Pistol Pete$ 05/27/15 12:33:58 PM
#15235   Yeah it is great. Paul is often InvestorStemCell 05/27/15 12:09:59 PM
#15234   Quote, "I have met Dr. Paul Knoepfler several Captain Kirk 05/27/15 11:09:42 AM
#15233   try smaller brokers specializing in OTC companies. InvestorStemCell 05/27/15 10:07:03 AM
#15232   IMO 95% of the longs capitulated . InvestorStemCell 05/27/15 10:03:46 AM
#15231   solid questions . InvestorStemCell 05/27/15 09:55:29 AM
#15230   I have met Dr. Paul Knoepfler several times InvestorStemCell 05/27/15 09:48:39 AM
#15229   I have seen this show so many times InvestorStemCell 05/27/15 09:35:15 AM
#15226   Stem cell "WILD WEST" unregulated- says AP (Associated Captain Kirk 05/27/15 12:00:45 AM
#15225   Is BHRT cash desperate or in a major Captain Kirk 05/26/15 11:33:17 PM
#15224   Hey SuperFeed/InvestorStemCell, what do mean by impending financing? Investaholic33 05/26/15 09:51:27 PM
#15223   Money ushering change. This stock has not InvestorStemCell 05/26/15 09:28:08 PM
#15222   Why can't you respect my OPINION and not andyshow 05/26/15 05:00:06 PM
#15221 Priced at . andyshow 05/26/15 04:57:47 PM
#15220   LOL BS quote, "IMO they walked in with Captain Kirk 05/26/15 04:26:47 PM
#15219   someones accumulating 514 05/26/15 04:16:07 PM
#15218   IMO they walked in with a suit case andyshow 05/26/15 04:02:13 PM
#15217   Iron, nope- no clue either. Captain Kirk 05/26/15 11:51:48 AM
#15216   hey Captain I have never seen a IHUB ironguts 05/26/15 11:34:47 AM
#15215   Looks like we may have some non institutional gypsydoc 05/26/15 11:13:31 AM
#15214   $BHRT charts $Pistol Pete$ 05/26/15 10:19:57 AM
#15213   AMAZING, 4 MILLION volume and day's LOW taken Captain Kirk 05/26/15 10:18:35 AM
#15212   hummm someone still dumping not? a 2 million pepemartinez 05/26/15 09:47:31 AM
#15211   AM Level II, BMAK has it "bracketed" on Captain Kirk 05/26/15 09:45:15 AM
#15210   LOL, Like Holy Cow, LOL. Like LOL already. LOL Big_Mullet 05/25/15 11:14:02 PM
#15209   LOL quote, "we look forward to rewarding Dr. Captain Kirk 05/25/15 11:10:18 PM
#15208   We greatly appreciate Dr. Murphy’s continuing support and micromoney 05/25/15 10:20:37 PM
#15207   What do you think needs to happen to akiaki 05/25/15 09:46:18 PM
#15206   Why doesn't Mike Tomas buy some stock instead toddski 05/25/15 09:34:08 PM